Puma Biotechnology (PBYI) revenue and earnings history
Puma Biotechnology reported revenue of $228M for fiscal 2025 (year ended Dec 31, 2025), −0.9% on the year before, and net income of $31.1M.
Over 8 years, from fiscal 2017 to fiscal 2025, revenue grew at a compound rate of +30.2% a year.
Revenue and net income, 15 fiscal years
Annual figures, newest first
| Fiscal year | Revenue | Operating income | Net income | Operating cash flow | Capital expenditure | Free cash flow | Stock-based pay | Share buybacks | Dividends paid | Cash at year end | Total debt at year end | Report |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025ended Dec 31, 2025 | $228M−0.9% | $37.3M | $31.1M | $41.8M | $71K | $41.7M | $6.94M | — | — | $29.6M | $22.7M | 10-K |
| 2024ended Dec 31, 2024 |
The latest quarter, insider trades and fund moves: Puma Biotechnology (PBYI) on OQRO.
Common questions
What was Puma Biotechnology's revenue in fiscal 2025?
$228M for the year ended Dec 31, 2025, as reported in its 10-K filed Feb 26, 2026. That is −0.9% on fiscal 2024 ($230M).
How fast has Puma Biotechnology's revenue grown?
From $27.7M in fiscal 2017 to $228M in fiscal 2025: a compound annual growth rate of +30.2% over 8 years. This is arithmetic on the filed figures and says nothing about the years ahead.
Where these figures come from
The SEC’s companyfacts data: every figure Puma Biotechnology tagged in XBRL in its annual and quarterly reports since 2009 (some reports carry a few earlier years as comparatives). For each fiscal year OQRO keeps the twelve-month totals from the annual report and the cash and debt at year end, and when a later report restates a year, the later figure. Read again whenever the company files.
Figures are as reported, in US dollars, with no adjustment for acquisitions, disposals or one-off items. Earnings per share are left out because a stock split changes them between reports. This page describes the past and is not investment advice. No language model wrote it.
